Skip to content
OpenCapital
Get started

Theravance Biopharma TBPH Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$359M+63.2%
Precigen logo
PrecigenPGEN
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——

Other financials

Income statement

See full
Revenue$17.7M+15.0%
Operating income-$9.5M+34.3%
Net income-$4.9M+63.7%
EPS (diluted)-$0.10+63.0%

Balance sheet

See full
Cash & equivalents$288.1M+160%
Total debt$40.5M-15.9%
Total equity$290.6M+75.1%
Total assets$472.3M+37.5%

Cash flow

See full
Operating cash flow$73.3M+70.3%
CapEx$8.0K-95.8%
Free cash flow$59.6M+5,560%

Valuation

See full
Market cap$896.51M+68.7%
Enterprise value$648.91M+38.3%
P/E7.8×—
P/S8.2×0.0×

Profitability

See full
Gross margin60.8%—
Operating margin1.2%+0.6pp
Net margin104.3%+71.4pp
FCF margin221.9%+206pp

Returns & leverage

See full
Return on equity50.2%+36.2pp
Debt / equity0.1×-0.2×
Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Theravance Biopharma's proceeds from sale and maturity of available for sale securities?
Theravance Biopharma (TBPH) reported proceeds from sale and maturity of available for sale securities of $96M in Q1 2026.
How has Theravance Biopharma's proceeds from sale and maturity of available for sale securities changed year-over-year?
Theravance Biopharma's proceeds from sale and maturity of available for sale securities increased by 194.5% year-over-year, from $32.6M to $96M.
What is the long-term trend for Theravance Biopharma's proceeds from sale and maturity of available for sale securities?
Over 3 years (2021 to 2025), Theravance Biopharma's proceeds from sale and maturity of available for sale securities has grown at a -20.7% compound annual growth rate (CAGR), from $286.2M to $142.98M.